Precision Optics Eyes Capital Infusion Amid Record Growth and Margin Woes

GARDNER, Mass. – March 26, 2026 – Precision Optics Corporation, Inc. (NASDAQ: POCI), a key supplier of advanced optical systems for the medical and defense industries, announced today it is commencing a public offering of its common stock. The move comes as the company navigates a period of unprecedented revenue growth coupled with significant pressure on its profit margins, creating a complex picture for investors.

The proposed underwritten offering, managed solely by Lucid Capital Markets, aims to raise fresh capital, although the final size and terms remain subject to market conditions. The funds are earmarked for working capital and general corporate purposes, a broad mandate that gives the company flexibility as it scales operations in highly competitive, technology-driven sectors.

A Tale of Two Financials

The timing of the offering is critical. Precision Optics is in the midst of a remarkable growth spurt, reporting record revenues in the first two quarters of its 2026 fiscal year. In its first quarter ending September 30, 2025, revenue surged 59% year-over-year to $6.68 million. This was followed by another record in the second quarter ending December 31, 2025, with revenue hitting $7.37 million, a 63% increase from the prior year. The company's management has projected this trajectory to continue, guiding for full-year fiscal 2026 revenue between $26 million and $28 million, representing growth of 36% to 47%.

However, this explosive top-line growth masks underlying profitability challenges. The company's gross margin has eroded significantly, dropping from 26.6% in the first quarter of fiscal 2025 to just 14.2% a year later. The decline steepened dramatically in the second quarter of fiscal 2026, when gross margin plummeted to a mere 2.8%.

This margin compression has led to substantial losses. The company reported a net loss of $1.64 million in its first quarter and $1.78 million in its second quarter. Adjusted EBITDA, a measure of operating profitability, was also negative, landing at $(1.2) million and $(1.5) million for the respective quarters. Company officials have attributed the margin squeeze to "operational investments and ramp-related inefficiencies" as they scale up production to meet demand. They have expressed expectations for margins to improve in the latter half of the fiscal year, but the current cash burn underscores the urgent need for the capital this offering seeks to provide.

Offering Mechanics and Investor Implications

The offering is being made pursuant to a shelf registration statement on Form S-3, which was filed with the Securities and Exchange Commission (SEC) in June 2024. This allows the company to issue securities more quickly in response to market opportunities. While the final details are pending, a preliminary prospectus indicates the offering may include not only common stock but also pre-funded warrants, which can be exercised into common stock at a later date.

For existing shareholders, any new issuance of stock brings the risk of dilution, meaning their ownership stake in the company is reduced. The exact level of dilution will remain unknown until the offering is priced and the final number of new shares is determined. Interestingly, the market's reaction ahead of the formal announcement was positive. POCI's stock price gained over 9% in the week prior and recently rose above its 200-day moving average, trading at $4.20 with a market capitalization of nearly $35 million. This suggests some investors may see the company as undervalued and the capital raise as a necessary step to fuel its long-term potential.

This is not the company's first trip to the capital markets in recent years. Precision Optics raised approximately $5.1 million in a direct offering in February 2025 and another $1.4 million in August 2024, using those funds for debt repayment, facility expansion, and working capital. The recurring need for external funding highlights the capital-intensive nature of its business.

Fueling the Future of Surgery and Defense

The capital being raised is intended to power a company at the forefront of several cutting-edge technological fields. Founded in 1982, Precision Optics has carved out a niche by designing and manufacturing highly specialized optical instruments that are critical components in next-generation medical devices and defense systems.

In the healthcare sector, the company's proprietary micro-optics and 3D imaging technologies are enabling the shift toward smaller, more capable tools for minimally invasive surgery. As surgical procedures become less invasive, the demand for high-resolution, microscopic imaging systems that can navigate complex anatomy grows. Precision Optics provides these solutions, including complex endocouplers and specialized endoscopes that are integral to the rapidly expanding field of robotic surgery.

The same technical proficiency is leveraged for the defense and aerospace industries. The company develops optical systems that meet stringent military requirements for size, weight, and power (SWaP), which are critical for applications in surveillance, targeting systems, and advanced augmented reality displays for pilots. The ability to produce durable, high-performance micro-optics makes the company a key partner for leading defense contractors. This new infusion of cash could accelerate development and production in these high-demand areas.

Competing in a High-Growth Arena

Precision Optics operates in a dynamic and rapidly expanding market. The global advanced optics industry is projected to more than double in the next decade, growing from roughly $314 billion in 2024 to over $750 billion by 2034. This growth is driven by relentless technological innovation, the integration of artificial intelligence, and sustained demand from key sectors.

However, the company faces stiff competition. It competes with a wide range of firms, from specialized optics houses like Edmund Optics and Rochester Precision Optics to divisions of industrial giants like ZEISS, Corning, and Nikon. In the medical device space, its performance is often compared to companies like Apyx Medical and Pro-Dex.

To succeed, Precision Optics must not only innovate but also execute its production ramp-up efficiently. The proposed stock offering is a strategic bet that with sufficient capital, the company can overcome its current margin challenges, solidify its position in the supply chain for medical and defense leaders, and capture a larger share of this lucrative and strategically important market. The outcome of this offering and the company's ability to translate the funds into profitable growth will be closely watched by investors and industry observers alike.